Clinical Advances in Immune Thrombocytopenia: Integrating New Therapies

Clinical Advances in Immune Thrombocytopenia: Integrating New Therapies

Friday, December 4, 2020
Webinar -- 11:00 AM PT
https://www.clinicaloptions.com/ITPWinter2020Join1

Agenda

  • Case Discussion 1: Optimizing the Management of Newly Diagnosed ITP
  • Case Discussion 2: Therapeutic Options for Patients With Previously Treated ITP
  • Caring for Special Populations of Patients With ITP/Thrombocytopenia

Faculty

Program Director
David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Chief of Hematology
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Faculty
Keith R. McCrae, MD

Professor of Molecular Medicine
Department of Hematology and Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Faculty
Michael D. Tarantino, MD

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in using new and emerging therapeutic options for patients with ITP.

Target Audience
This program is intended for hematologists and other clinicians involved in the management of patients with immune thrombocytopenia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify treatment-naive patients with ITP who would benefit from intensified therapy to enhance remission rates
  • Plan individualized second-line treatment regimens for ITP that is unresponsive to traditional steroids and splenectomy
  • Select optimal therapy for patients with ITP who have had an insufficient response to corticosteroids, immunoglobulins, splenectomy, and/or a thrombopoietin receptor agonist
  • Evaluate therapeutic strategies to manage thrombocytopenia in special populations of patients, including children, athletes, military, first responders, or those with chronic liver disease or undergoing a planned medical procedure
  • Discuss the available data and ongoing clinical trials investigating novel agents and combination regimens for the treatment of ITP

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.